Novel Testing to Elucidate Reproductive Outcomes of ZIKV Infection - Olympics 2016
阐明 ZIKV 感染生殖后果的新测试 - 2016 年奥运会
基本信息
- 批准号:9265224
- 负责人:
- 金额:$ 30.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2017-09-01
- 项目状态:已结题
- 来源:
- 关键词:AfricaAge-MonthsAmericasAntibodiesBirthBloodBody FluidsBrainBrazilCenters for Disease Control and Prevention (U.S.)Contraceptive UsageCountryCulicidaeDevelopmentDisease OutbreaksFlavivirusGeographic LocationsGrowthHawaiiHealthHuman MilkHuman ResourcesIncidenceIndividualInfantInfectionLifeLongitudinal StudiesMaternal-Fetal TransmissionMicrocephalyMorbidity - disease rateNucleic AcidsOutcomePerinatalPersonsPregnancyPregnancy OutcomePublic HealthRegimenResearchRiskRisk FactorsRouteSalivaScheduleSeminal fluidSexual PartnersTechnologyTestingTimeTravelUnited StatesUniversitiesUtahVaginaVirus DiseasesWomanWorld Health OrganizationZika Viruscohortcongenital anomalycontraceptive effectivenessdisorder preventionfetal infectioninfant outcomeinterestmennovelnucleic acid detectionpregnantpreventpublic health emergencypublic health prioritiesreproductivetransmission processviral transmission
项目摘要
Zika virus (ZIKV) is a mosquito-borne flavivirus that has emerged in the Americas with local transmission identified in 30 countries and territories as of April 2016, including Brazil. Most persons (80%) with ZIKV infection are asymptomatic and ZIKV may be sexually transmitted, placing individuals who may not have travelled at risk. Maternal-fetal transmission of ZIKV has also been documented. In April 2016, the US Centers for Disease Control and Prevention confirmed that fetal infection with ZIKV was the cause of microcephaly and other severe brain anomalies that result in permanent morbidity in surviving infants. Many questions remain regarding ZIKV infection, including the duration and potential for sexual or perinatal transmission of ZIKV from body fluids; the short and long-term reproductive outcomes of individuals infected with ZIKV; and the outcomes for infants born to men and women with either symptomatic or asymptomatic ZIKV infection. The University of Utah partnered with the United States Olympic Committee (USOC) to prepare for the 2016 Summer Olympic and Paralympic Games scheduled to occur in Brazil, the epicenter of the ZIKV outbreak in the Americas. The partnership focuses on understanding the dynamics of ZIKV infection in order to better protect the health of athletes and staff who will participate in the 2016 Games. This partnership also offers an exceptional opportunity for research that has the potential to answer many of the important research questions identified by the FOA PAR-16-106 “Rapid Assessment of ZIKV Complications (R21).” The proposed USOC cohort is unique in that it includes men and women in their reproductive years who are interested in conceiving after the Games. Their ongoing relationship with the USOC offers an opportunity for longitudinal study that will be of enormous benefit to the Americas, including the US, and to other geographic areas facing the emergence of ZIKV. We propose the following Specific Aims: Aim 1) Determine incidence of and risk factors for ZIKV infection in a cohort of athletes coaches, staff, other personnel traveling to Brazil with the US Olympic Committee (USOC) as part of the 2016 Olympic and Paralympic games and their sexual partners through antibody testing; Aim 2a) Determine in ZIKV infected individuals, the duration of ZIKV nucleic acid detection in specific body fluids that may be associated with sexual or perinatal transmission of the virus including blood, saliva, semen, and vaginal secretions using novel PCR technology; and Aim 2b) Evaluate the reproductive outcomes of ZIKV infected individuals for one year including contraceptive use and pregnancy.
寨卡病毒(ZIKV)是一种蚊媒黄病毒,已在美洲出现,截至2016年4月,在包括巴西在内的30个国家和地区发现了本地传播。大多数感染ZIKV的人(80%)没有症状,ZIKV可能通过性传播,使可能没有旅行过的人处于危险之中。ZIKV的母婴传播也有记录。2016年4月,美国疾病控制和预防中心证实,胎儿感染ZIKV是导致存活婴儿永久性发病的小头畸形和其他严重脑异常的原因。关于ZIKV感染仍然存在许多问题,包括ZIKV从体液的性传播或围产期传播的持续时间和潜力;感染ZIKV的个体的短期和长期生殖结果;以及患有症状性或无症状ZIKV感染的男性和女性所生婴儿的结果。犹他州大学与美国奥林匹克委员会(USOC)合作,为定于巴西举行的2016年夏季奥运会和残奥会做准备,巴西是美洲ZIKV疫情的中心。该合作伙伴关系的重点是了解ZIKV感染的动态,以便更好地保护参加2016年奥运会的运动员和工作人员的健康。该合作伙伴关系还提供了一个特殊的研究机会,有可能回答FOA PAR-16-106“ZIKV并发症快速评估(R21)”确定的许多重要研究问题。拟议中的USOC队列是独一无二的,因为它包括处于生育年龄的男性和女性,他们有兴趣在奥运会后怀孕。他们与USOC的持续关系提供了一个纵向研究的机会,这将对包括美国在内的美洲以及面临ZIKV出现的其他地理区域带来巨大好处。我们提出了以下具体目标:目标1)确定作为2016年奥运会和残奥会的一部分随美国奥委会(USOC)前往巴西的运动员、教练、工作人员和其他人员队列中ZIKV感染的发生率和风险因素通过抗体检测;目的2a)确定在ZIKV感染的个体中,在可能与病毒的性传播或围产期传播相关的特定体液(包括血液、唾液、精液,目的2b)评估ZIKV感染个体一年的生殖结果,包括避孕药具的使用和怀孕。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carrie L. Byington其他文献
Carrie L. Byington的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carrie L. Byington', 18)}}的其他基金
University of Utah Center for clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8720945 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8743323 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for Clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8899720 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for Clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8743325 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
Clinical and Translational Science NRMN Furthering a Diverse Biomedical Workforce
临床和转化科学 NRMN 促进多元化的生物医学劳动力
- 批准号:
8661445 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8720938 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8899719 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for Clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8720951 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8743324 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别:
University of Utah Center for clinical and Translational Science
犹他大学临床和转化科学中心
- 批准号:
8899718 - 财政年份:2013
- 资助金额:
$ 30.2万 - 项目类别: